Gastric cancer (GC) is a global health challenge. With an estimated 1,089,103 new cases
and 768,793 deaths in 2020, GC is the fifth most common type of cancer and the fourth …

Methods: Treatment-naive GC patient group (n= 29) was selected. Whole exome
sequencing (WES) of GC tissue was performed, and a unique 38-gene panel for deep …

Gastric cancer (GC) is one of the most common malignant tumors with poor prognosis
worldwide, mainly due to the lack of suitable modalities for population‑based screening and …

Background Molecular cancer profiling may lead to appropriate trials for molecularly
targeted therapies. Cell-free DNA (cfDNA) is a promising diagnostic and/or prognostic …

Objective Screening and early diagnosis of gastric cancer (GC) are crucial for improved
prognosis. However, gastroscopic screening is not feasible in large populations due to its …

Next-generation sequencing-based genomic profiling facilitates biomarker detection by cell-
free DNA (cfDNA) liquid biopsy. However, the efficiency of mutation calling and the …

Tumor cells shed DNA into the plasma.“Liquid biopsy” analysis of mutations or other
genomic alterations in circulating cell-free DNA (cfDNA) may provide us with a tool to detect …

Background Gastric cancer is the fifth most common cancer type. Most patients are
diagnosed at advanced stages with poor prognosis. A non-invasive assay for the detection …

Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: A systematic review -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Liquid biopsies are providing new opportunities for detection of residual disease in cell-free
DNA (cfDNA) after surgery but may be confounded through identification of alterations …